Table 2.

Postoperative adrenal insufficiency and follow up in all patients (n=81) and by clinical severity of cortisol excess.

	n=81	MACE 30 (37.0%)	Moderate CS 24 (29.7%)	Severe CS 27 (33.3%)	P
Median follow-up, months	14.0 (6.5–36.0)	18.0 (11.8–34.5)	11.5 (3.0–40.0)	12.0 (6.0–34.0)	0.37
Number of patients with postoperative 8AM serum cortisol 24 h off any GC	33 (40.7%)	16 (53.3%)	10 (41.7%)	7 (25.9%)	0.11
Immediate postoperative serum cortisol, μg/dL, nmol/L, n=33 (Reference range 7–25 μg/dL, 193–690 nmol/L)	3.1 (1.3–5.6) 86 (35–155)	3.2 (1.1–6.1) 88 (33–167)	3.9 (1.5–6.0) 108 (40–164)	1.6 (1.2–4.3) 44 (33–119)	0.68
Patients who received perioperative IV steroids	63 (77.8%)	17 (56.7%)	22 (91.7%)	24 (88.9%)	0.002
Hydrocortisone-equivalent dose at the start of the glucocorticoid therapy, mg/day	40 (30–60)	37.5 (20–40)	40 (21.2–50)	60 (40–80)	0.002
Type of glucocorticoid therapy:
Hydrocortisone	39 (48.1%)	18 (60.0%)	9 (37.5%)	12 (44.4%)	0.23
Prednisone	42 (51.9%)	12 (40.0%)	15 (62.5%)	15 (55.6%)	0.23
8AM serum cortisol at recovery, μg/dL	11 (10.5–14.0)	11 (10.0–15.5)	11.0 (10.0–15.5)	11.7 (10.0–13.3)	0.95
(Reference range 7–25 μg/dL, 193–690 nmol/L)	306 (276–387)	304 (290–386)	304 (276–428)	323 (276–368)

Continuous data are summarized as median and interquartile ranges. Categorical data are presented as frequencies and percentages. All P-values <0.05 were considered significant.

Abbreviations used: CS, Cushing syndrome; GC, glucocorticoid; IV, intravenous; MACE, mild autonomous cortisol excess.